Login
$AUTL
$1.16 +$0.02 (1.75%) After hours

$AUTL SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 S-8
12 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 10-Q
10 Nov 2026 SCHEDULE 13D/A
10 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95%...

22 Sep 2026 EFFECT
22 Sep 2026 424B3
15 Sep 2026 DEL AM
14 Sep 2026 S-3
03 Sep 2026 Form 4: Piccina Cintia, U.S. CCO & Country Gen Manager

Received 20,000 shares by exercise or conversion ($47K) · Sold 6,713 shares ($15.7K)

02 Sep 2026 144
28 Aug 2026 SCHEDULE 13D/A
14 Aug 2026 SCHEDULE 13G/A
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates August 11, 2026 at 7:00 AM EDT Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an incre...

03 Aug 2026 8-K: Regulation FD Disclosure; Other Events

Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors August 3, 2026 at 7:13 AM EDT Company reports preliminary Q2 2026 AUCATZYL net ...

03 Aug 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

Other Equity Interests owned or held by the Issuer or its Subsidiaries

01 Jul 2026 Form 4: Young William D, Director

Granted 31,667 Restricted Share Units · Granted 47,500 Share Option (Right to Buy)

01 Jul 2026 Form 4: Rao Madduri Ravin, Director

Granted 31,667 Restricted Share Units · Granted 47,500 Share Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support